Pharnext SA (FR0011191287 - ALPHA) (the "Company") today announces its Board of Directors has appointed Piers Morgan as a new, independent, non-executive member following a comprehensive search and selection process.
French biopharmaceutical company Pharnext has announced a research and development (R&D) agreement with Galapagos to generate a new pipeline of synergistic drug combinations.